Mobocertinib, Asciminib & Surufatinib Among Latest New Filings In EU
The European Medicines Agency has added nine new products to its latest list of medicines that are under review for potential EU marketing authorization.
You may also be interested in...
The European Medicines Agency’s human medicines committee, the CHMP, is expected to decide whether 11 drugs should be recommended for marketing approval during its latest monthly meeting, which started today.
Vutrisiran, Alnylam’s investigational RNAi therapeutic for treating hereditary transthyretin-mediated amyloidosis in adults with polyneuropathy, is among the latest new medicines that have been submitted for review for potential pan-EU approval.
Asciminib, Novartis's drug for patients with chronic myeloid leukemia, is among the latest new medicines that have been submitted for pan-EU approval.